GenomeDx

The group now states that men with unfavorable intermediate-risk or high-risk disease can consider testing with Myriad's Prolaris or GenomeDx's Decipher.

Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.